Size Matters: Superior Efficacy of α Particle Radioimmunotherapy in Micrometastases versus Macrometastases.

Radiopharmaceuticals, which emit either α or β particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted α particle-emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus macrometastatic disease. See related article by Bidkar et al., p. 2963.